BoZo Research Center Selects Instem as SEND Outsourcing Partner for Japanese Market
BoZo Research Responds to Strong Market Demand and Becomes SEND-Enabled
CONSHOHOCKEN, PA - (BUSINESS WIRE) – June 2, 2016 - -Instem, a leading provider of IT solutions to the global early development healthcare market, announced today that BoZo Research Center (BoZo) has chosen them as their exclusive SEND outsourcing partner in Japan.
BoZo has been serving the preclinical research community for over 40 years and is one of the leading contract research organizations in Japan with nearly 500 employees located across four sites.
Helping them meet increased market demand, Instem will be complementing the existing team at BoZo, providing SEND data conversion and consulting services for organizations throughout Japan. Instem will begin providing services this year and BoZo expects up to 100 preclinical studies will need to be converted into SEND during 2017.
“The market in Japan requires high quality results that are reliable and can be produced cost effectively,” states Koji Takashima, Vice President, Sales and Market Development at BoZo. “Through Instem, we now have access to the world’s foremost experts in SEND and our entire client community will be able to Submit with Confidence™.”
Instem’s submit™-SEND tools and services are the most widely adopted in the industry, supporting over 34 client sites across 13 countries. The Instem team has led and participated in the creation of the SEND standard for more than 10 years and brings over 30 years of experience in developing, delivering and supporting world-class nonclinical systems and solutions for the scientific community.
“BoZo has a long track record of providing excellent customer support and their development of this strategic relationship has shown us how committed they are to SEND and their mission of creating a safer society,” comments Terukazu Kitahara, Japan Regional Manager at Instem. “Through our agreement, BoZo will be able to meet immediate demand for SEND study data conversions while ensuring it is well positioned to handle what will be a large influx of orders in 2017 as the SEND mandate continues to permeate the global market.”
The Food & Drug Administration reports that 11% of new drug approvals in 2015 were from Japanese organizations and that rate is expected to continue and possibly rise in the future. Instem has been serving the Japanese marketplace since 2005 and during 2015 has opened a new office in Tokyo, has hired additional local staff and increased its technology offerings to help meet market demand. Instem has already signed two other SEND contracts during 2016 in Japan and along with this agreement from BoZo is well poised to further increase its global leadership position.
SEND Showcase at the 43rd Annual Meeting of the Japanese Society of Toxicology (JSOT)
BoZo, along with representatives from Instem, will be holding an open luncheon during this year’s JSOT exhibition that is being held in Nagoya, Japan from June 29 through July 1st. Anyone interested in learning more are encouraged to contact BoZo for more details at firstname.lastname@example.org.
About BoZo Research Center
BoZo Research offers a wide range of services from the initial stages of drug development to safety studies through its Japanese-based facilities as well as through their Montreal-based subsidiary, ITR Canada. In addition to the pharmaceutical market, BoZo supports government research programs and agencies as well as public and private universities.
Learn more about their mission and purpose at www.bozo.co.jp
Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organizations for data-driven decision making leading to safer, more effective products.
Instem’s portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonization of actionable scientific information.
Instem supports over 450 clients through full service offices in the United States, United Kingdom Japan, India and China.
Gary Mitchell (US HQ)
Julie Jones (UK HQ)
Tel: +44 (0) 1785 825600